Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601

Watchlist Manager
Shenzhen Kangtai Biological Products Co Ltd Logo
Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
Watchlist
Price: 18.1 CNY -4.99% Market Closed
Market Cap: 20.2B CNY
Have any thoughts about
Shenzhen Kangtai Biological Products Co Ltd?
Write Note

Shenzhen Kangtai Biological Products Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen Kangtai Biological Products Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
Cost of Revenue
-ÂĄ531m
CAGR 3-Years
-15%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cost of Revenue
-ÂĄ2.7B
CAGR 3-Years
-77%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cost of Revenue
-ÂĄ992.7m
CAGR 3-Years
-28%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cost of Revenue
-ÂĄ5B
CAGR 3-Years
-54%
CAGR 5-Years
-46%
CAGR 10-Years
-33%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cost of Revenue
-ÂĄ35.1B
CAGR 3-Years
-49%
CAGR 5-Years
-51%
CAGR 10-Years
-62%
Imeik Technology Development Co Ltd
SZSE:300896
Cost of Revenue
-ÂĄ140.8m
CAGR 3-Years
-36%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Kangtai Biological Products Co Ltd
Glance View

Market Cap
20.2B CNY
Industry
Biotechnology

Shenzhen Kangtai Biological Products Co., Ltd. engages in the manufacture, sale, and research and development of human vaccines. The company is headquartered in Shenzhen, Guangdong and currently employs 2,445 full-time employees. The company went IPO on 2017-02-07. is a China-based company and mainly engaged in research and development, manufacture and sale of vaccine. The main products of the company are recombinant hepatitis B virus, haemophilus influenzae type b combined vaccine, measles rubella combined attenuated live vaccine, non-cell Bai Bai Po haemophilus influenzae combined vaccine and other products. The firm operates its businesses primary in domestic market.

Intrinsic Value
22.35 CNY
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Shenzhen Kangtai Biological Products Co Ltd's Cost of Revenue?
Cost of Revenue
-531m CNY

Based on the financial report for Jun 30, 2024, Shenzhen Kangtai Biological Products Co Ltd's Cost of Revenue amounts to -531m CNY.

What is Shenzhen Kangtai Biological Products Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-27%

Over the last year, the Cost of Revenue growth was -5%. The average annual Cost of Revenue growth rates for Shenzhen Kangtai Biological Products Co Ltd have been -15% over the past three years , -27% over the past five years .

Back to Top